ZTA Biotech

ZTA Biotech appears to have been a small private biotech startup focused on diagnostics and computational biology, with public visibility centered on a January 2021 announcement of a COVID-19 immunoglobulin G antibody test based on the ELISA protocol. The company described itself as the intellectual property holder for the protocol and said it used an in-house software package for simulation and modeling of critical protein-protein interactions to support product development. Its lead known product was a qualitative and semi-quantitative SARS-CoV-2 immunoglobulin G serology assay intended for post-vaccination and prior-exposure assessment. Publicly available evidence does not show a broader sustained pipeline, financing history, or continuing operating footprint after the 2021 period. The company website referenced in trade listings is no longer clearly verifiable, so the business appears inactive or at least not meaningfully operating today.